AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7877082 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated recessions)
Number of subjects: 15
Study 3138446 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressings changed three times per week
Number of subjects: 168
Study 3138446 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite dressings changed every 7th day (OpS-7)
Number of subjects: 168
Study 3138446 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite dressings changed every 10th day (OpS-10)
Number of subjects: 168
Study 3138446 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite dressings changed twice weekly (OpS-ICU)
Number of subjects: 168
Study 3138446 — intervention group
Group type: EXPERIMENTAL
Intervention: Septicemia attributable to causes apart from catheter sepsis
Number of subjects: 168
Study 31160034 — intervention group
Group type: EXPERIMENTAL
Intervention: S aureus colonization
Number of subjects: 312
Study 29252120 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing the way stories frame depression
Number of subjects: 0
Study 29252120 — intervention group
Group type: COMPARATOR
Intervention: Earlier scholarship
Number of subjects: 0
Study 27399068 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft lateral wedge arch support (LWAS) insoles
Number of subjects: 90
Study 27399068 — intervention group
Group type: COMPARATOR
Intervention: Rigid lateral wedge arch support (LWAS) insoles
Number of subjects: 90
Study 24608200 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (9 weeks)
Number of subjects: 1010
Study 24608200 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 1010
Study 23114388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 × 20 minutes per week for 12 weeks)
Number of subjects: 67
Study 19602839 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (isoleucine:leucine:valine=1:2.3:1.2) at 0.1 g/kg body weight 15 min before squat exercise
Number of subjects: 0
Study 19602839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin) at 0.1 g/kg body weight 15 min before squat exercise
Number of subjects: 0
Study 19602839 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 0
Study 17804312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand/rotary technique
Number of subjects: 40
Study 17804312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand/rotary/ultrasound technique
Number of subjects: 40
Study 14678375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical prostaglandin E2 (1.5 mg in 20 mL 0.9% saline) plus oral bethanechol chloride (50 mg four times daily) for 6 weeks
Number of subjects: 19
Study 14678375 — intervention group
Group type: COMPARATOR
Intervention: Saline instillation plus placebo tablets for 6 weeks
Number of subjects: 19
Study 12403032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovamycin
Number of subjects: 40
Study 12403032 — intervention group
Group type: COMPARATOR
Intervention: Augmentin
Number of subjects: 40
Study 10210973 — intervention group
Group type: EXPERIMENTAL
Intervention: Two nucleoside analogues and one protease inhibitor
Number of subjects: 61
Study 7596211 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment teams with extensive training in in vivo treatment
Number of subjects: 185
Study 7596211 — intervention group
Group type: COMPARATOR
Intervention: Case management program emphasizing office-based treatment
Number of subjects: 185
Study 7596211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed prospective/retrospective payment
Number of subjects: 185
Study 7596211 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall services provided
Number of subjects: 185
Study 2196060 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 77
Study 2196060 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A
Number of subjects: 77
Study 656357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine in an oily solution
Number of subjects: 0
Study 656357 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine in aqueous solution
Number of subjects: 0
Study 6797663 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative drugs (specific drugs not mentioned)
Number of subjects: 88
Study 6797663 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 88
Study 6797663 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free interval between drugs
Number of subjects: 88
Study 6797663 — intervention group
Group type: COMPARATOR
Intervention: Gold, penicillamine, levamisole (as first second-line drug)
Number of subjects: 88
Study 30719351 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic stretch technique
Number of subjects: 20
Study 30719351 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual diaphragm release technique
Number of subjects: 20
Study 30719351 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 20
Study 28486495 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors
Number of subjects: 21297
Study 25701002 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg DHA
Number of subjects: 89
Study 25701002 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg DHA
Number of subjects: 89
Study 25701002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 24456065 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH) HCl
Number of subjects: 284
Study 24456065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 22447579 — intervention group
Group type: EXPERIMENTAL
Intervention: GCBT+HA
Number of subjects: 38
Study 22447579 — intervention group
Group type: EXPERIMENTAL
Intervention: GCBT
Number of subjects: 38
Study 22447579 — intervention group
Group type: COMPARATOR
Intervention: BIB
Number of subjects: 38
Study 19568197 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐arginine hydrochloride capsules (7.2 g x d(‐1))
Number of subjects: 7
Study 19568197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 7
Study 17311785 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance of digit extension provided by a novel cable orthosis
Number of subjects: 15
Study 17311785 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance provided by a novel pneumatic orthosis
Number of subjects: 15
Study 17311785 — intervention group
Group type: COMPARATOR
Intervention: No assistance provided
Number of subjects: 15
Study 15607097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-suppressed subtraction MRI
Number of subjects: 94
Study 12070626 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training for 12 weeks
Number of subjects: 19
Study 12070626 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 19
Study 10409565 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg/day for 5 days)
Number of subjects: 8
Study 10409565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (trial 1)
Number of subjects: 8
Study 8567517 — intervention group
Group type: EXPERIMENTAL
Intervention: Precooling test (Pret)
Number of subjects: 8
Study 8567517 — intervention group
Group type: COMPARATOR
Intervention: Control test (Cont)
Number of subjects: 8
Study 2155697 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (four cycles) after radiotherapy
Number of subjects: 149
Study 2155697 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 149
Study 2155697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (cisplatin-vindesine followed by 6000 cGy of thoracic irradiation)
Number of subjects: 149
Study 2155697 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy (vindesine-cisplatin)
Number of subjects: 149
Study 2155697 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete response
Number of subjects: 149
Study 2155697 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with partial or minor response
Number of subjects: 149
Study 2155697 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (chemotherapy followed by radiotherapy)
Number of subjects: 149
Study 465407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine and phenylephrine
Number of subjects: 76
Study 465407 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridectomy from the first group
Number of subjects: 76
Study 31868149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin (40 mg capsule every 12 hours for six weeks)
Number of subjects: 71
Study 31868149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar components of nanomicelle curcumin capsules without curcumin)
Number of subjects: 71
Study 30918037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education intervention
Number of subjects: 40
Study 30918037 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based physiotherapy active control
Number of subjects: 40
Study 27533333 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose solution administered orally 2 minutes prior to PIV catheter insertion
Number of subjects: 40
Study 27533333 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution administered orally 2 minutes prior to PIV catheter insertion
Number of subjects: 40
Study 26465927 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (900 billion live bacteria)
Number of subjects: 19
Study 26465927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 19
Study 23111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 100 mg administered to the mid‐small intestine
Number of subjects: 8
Study 23111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 100 mg administered to the large intestine
Number of subjects: 8
Study 23111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of the IR tablet of RE
Number of subjects: 8
Study 23111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional gastrointestinal delivery of RE
Number of subjects: 8
Study 21871979 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 51
Study 21871979 — intervention group
Group type: COMPARATOR
Intervention: Conventional 4-port laparoscopic cholecystectomy (4-port LC)
Number of subjects: 51
Study 19840529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg b.i.d.)
Number of subjects: 22
Study 19840529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (b.i.d.)
Number of subjects: 22
Study 17086074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus-coping therapy (TCT) with TCI provision
Number of subjects: 70
Study 17086074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus-coping therapy (TCT) without TCI devices
Number of subjects: 70
Study 17086074 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no treatment for 12 months)
Number of subjects: 70
Study 15683142 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 15683142 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto‐titrating Positive Airway Pressure (APAP)
Number of subjects: 0
Study 15683142 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 0
Study 15683142 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 0
Study 12392836 — intervention group
Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 24
Study 12392836 — intervention group
Group type: COMPARATOR
Intervention: RVOT pacing
Number of subjects: 24
Study 9863541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg nocte
Number of subjects: 19
Study 9863541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8574712 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant EGF administered subcutaneously
Number of subjects: 24
Study 8574712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2191753 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 100
Study 2191753 — intervention group
Group type: COMPARATOR
Intervention: Normal surgical gauze
Number of subjects: 100
Study 313873 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 33
Study 313873 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) in combination with intramuscularly administered C. parvum
Number of subjects: 33
Study 31364896 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented biofeedback training and physical therapy (Group C)
Number of subjects: 45
Study 31364896 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (Group A)
Number of subjects: 45
Study 31364896 — intervention group
Group type: COMPARATOR
Intervention: Augmented biofeedback training (Group B)
Number of subjects: 45
Study 31969136 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Intervention (FI)
Number of subjects: 122
Study 31969136 — intervention group
Group type: COMPARATOR
Intervention: Individual Intervention (II)
Number of subjects: 122
Study 28958737 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (cathodal, 20 min, 1.0 mA, 0.04 mA/cm2)
Number of subjects: 15
Study 28958737 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 26837463 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg oral atomoxetine
Number of subjects: 33
Study 26837463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25369014 — intervention group
Group type: EXPERIMENTAL
Intervention: Study guides on thyroid disorders and diabetes
Number of subjects: 46
Study 25369014 — intervention group
Group type: COMPARATOR
Intervention: Conventional training program
Number of subjects: 46
Study 23469599 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Fumai Injection (YFI) alone, 2.6 g YFI in 250 mL normal saline, once daily for 15 days
Number of subjects: 80
Study 23469599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate alone, 0.2 g twice daily for 15 days
Number of subjects: 80
Study 23469599 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Fumai Injection (YFI) combined with hydroxychloroquine sulfate, same dosages as Groups A and B for 15 days
Number of subjects: 80
Study 20203451 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple risk factor intervention strategy based on single‐pill amlodipine besylate/atorvastatin calcium
Number of subjects: 0
Study 20203451 — intervention group
Group type: COMPARATOR
Intervention: Usual-care strategy
Number of subjects: 0
Study 18790313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-based intervention delivered by trained primary health workers
Number of subjects: 463
Study 18790313 — intervention group
Group type: COMPARATOR
Intervention: Control group with untrained health workers making equal visits
Number of subjects: 463
Study 15863377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg per day for 24 weeks)
Number of subjects: 51
Study 15863377 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (one 12-Gy fraction on the day of starting bicalutamide)
Number of subjects: 51
Study 15863377 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide alone (150 mg per day)
Number of subjects: 51
Study 15863377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (in patients who developed gynaecomastia or breast pain)
Number of subjects: 51
Study 12002672 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Ginkgo biloba extract twice daily for 7 days
Number of subjects: 12
Study 12002672 — intervention group
Group type: COMPARATOR
Intervention: 80 mg Ginkgo biloba extract once daily for 7 days
Number of subjects: 12
Study 10330737 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer postcard
Number of subjects: 800
Study 10330737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no primer postcard)
Number of subjects: 800
Study 8983868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (19 amino acids, 240 kJ/h)
Number of subjects: 14
Study 8983868 — intervention group
Group type: COMPARATOR
Intervention: Control (isovolumic infusions of nutrient-free saline solution)
Number of subjects: 14
Study 8983868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 14
Study 8983868 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 1744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadimidine 250 mg
Number of subjects: 10
Study 1744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadimidine 500 mg
Number of subjects: 10
Study 1744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadimidine 750 mg
Number of subjects: 10
Study 1744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadimidine 1000 mg
Number of subjects: 10
Study 1744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial oral dose of 750 mg
Number of subjects: 10
Study 7063342 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion target only
Number of subjects: 0
Study 7063342 — intervention group
Group type: EXPERIMENTAL
Intervention: Varied targets (not criterion)
Number of subjects: 0
Study 7063342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single target (not criterion)
Number of subjects: 0
Study 7063342 — intervention group
Group type: COMPARATOR
Intervention: Control group (rested)
Number of subjects: 0
Study 31914147 — intervention group
Group type: EXPERIMENTAL
Intervention: iLookOut online education program
Number of subjects: 11065
Study 31377284 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab (fully human monoclonal IGF‐1R antagonist antibody)
Number of subjects: 0
Study 31377284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30382734 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile Justice Anger Management (JJAM) Treatment
Number of subjects: 70
Study 30382734 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study 27457560 — intervention group
Group type: EXPERIMENTAL
Intervention: YH0618 soup 6 days a week for 6 weeks
Number of subjects: 0
Study 27457560 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (Control)
Number of subjects: 0
Study 25004917 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation intervention (n=196)
Number of subjects: 389
Study 25004917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=193)
Number of subjects: 389
Study 25004917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 389
Study 23114224 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic decision support (EDS) tool for TIA/stroke management
Number of subjects: 0
Study 23114224 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 20127058 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg body weight remifentanil
Number of subjects: 60
Study 20127058 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 microg/kg body weight remifentanil
Number of subjects: 60
Study 20127058 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 microg/kg body weight remifentanil
Number of subjects: 60
Study 17040483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate periodontal therapy (early treatment)
Number of subjects: 193
Study 17040483 — intervention group
Group type: COMPARATOR
Intervention: Usual care followed by periodontal therapy (deferred treatment)
Number of subjects: 193
Study 16232154 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG-99 (6.25 mg t.i.d.)
Number of subjects: 170
Study 16232154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 16232154 — intervention group
Group type: EXPERIMENTAL
Intervention: MIG-99
Number of subjects: 170
Study 11937616 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial gun acquisitions
Number of subjects: 45
Study 11937616 — intervention group
Group type: EXPERIMENTAL
Intervention: Most recent gun acquisitions
Number of subjects: 45
Study 11937616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gun acquisition sources
Number of subjects: 45
Study 11937616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gun acquisition methods
Number of subjects: 45
Study 11937616 — intervention group
Group type: EXPERIMENTAL
Intervention: Community involvement in gun acquisition
Number of subjects: 45
Study 10195680 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 53
Study 7780891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin drops (0.3% solution, 10 drops)
Number of subjects: 49
Study 7780891 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin drops (0.3% solution, 10 drops) with erythromycin ointment post-surgery
Number of subjects: 49
Study 7780891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 49
Study 7780891 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 49
Study 1412681 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood drainage and transfusion device
Number of subjects: 0
Study 1412681 — intervention group
Group type: COMPARATOR
Intervention: Standard suction drainage
Number of subjects: 0
Study 4014191 — intervention group
Group type: EXPERIMENTAL
Intervention: antismoking intervention
Number of subjects: 935
Study 30924310 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-RS2 supplementation
Number of subjects: 0
Study 30924310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29775805 — intervention group
Group type: EXPERIMENTAL
Intervention: New subsolid nodules detected after baseline screening
Number of subjects: 7557
Study 29775805 — intervention group
Group type: EXPERIMENTAL
Intervention: New subsolid nodules
Number of subjects: 7557
Study 29775805 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsolid nodules with additional follow‐up screening
Number of subjects: 7557
Study 27356102 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (25%)
Number of subjects: 24
Study 27356102 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (15%)
Number of subjects: 24